Researchers to Clinicians: Don’t Neglect the Neuropsychiatric Symptoms of Friedreich’s Ataxia
November 27th 2024Poor balance and coordination are prominent features of Friedreich’s ataxia (FRDA). Czech researchers found that neuropsychiatric symptoms are also common among patients with FRDA.
Read More
Wearable Devices Help Assess Friedreich's Ataxia Severity Better Than In-Clinic Assessments
November 4th 2024The ability to gather continuous, objective data on physical activity and upper limb movements may allow for a more comprehensive understanding of the daily functional capacities of patients with Friedereich's ataxia.
Read More
Positive Pipeline Updates for Friedreich’s Ataxia
October 24th 2024After experiencing setbacks, PTC reported positive results for vatiquinone, its selective inhibitor of 15-Lipoxygenase (15-LO) enzyme, regulator of the energetic and oxidative stress pathways that are disrupted in Friedreich ataxia
Read More
How Do Skeletal Muscle Relaxants Fit Into Pain Management?
October 7th 2024A review of skeletal muscle relaxants shows that they don't work for pain from osteoarthritis, neuropathic pain and other conditions. Some see an opportunity for more tailored therapeutic strategies, improving patient outcomes.
Read More
Early Genetic Testing Avoids Treatment Delays for Patients with Friedreich's Ataxia
September 18th 2024Genetic and biochemical testing are crucial for improving outcomes for patients with Friedreich ataxia, according to speakers at a symposium at the European Association of Neurology Congress.
Read More
Improving Pain Self-Management Among Rural, Older Cancer Patients
August 13th 2024The management of pain in older adults with cancer remains a significant public health concern and an unmet medical need, particularly in rural areas. This demographic often encounters specific challenges, such as limited access to healthcare services, hesitancy to talk about pain, and misunderstandings about pain management.
Read More
Lexeo Therapeutics' LX2006 Shows Promise in Treating Friedreich's Ataxia Cardiomyopathy
August 9th 2024Given the lack of approved treatments for FA cardiomyopathy, LX2006's potential could represent a breakthrough for patients suffering from a disease characterized by severe cardiac complications.
Read More